HCW Biologics Signs Amended License and Co-Development Agreement with Beijing Trimmune Biotech
I'm PortAI, I can summarize articles.
HCW Biologics Inc. has signed an Amended and Restated License, Research and Co-Development Agreement with Beijing Trimmune Biotech Co., Ltd. The agreement includes the assignment of rights for the HCW11-006 molecule and an option for HCW9302 in China or Asia. Trimmune will pay a $7 million license fee, half in cash and half in equity. HCW Biologics retains rights for development in the Americas after Phase 1 trials. Trimmune will handle all related costs in its territory.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments